TAPENTADOL HYDROCHLORIDE Drug Patent Profile

Which patents cover Tapentadol Hydrochloride, and what generic alternatives are available?

Tapentadol Hydrochloride is a drug marketed by Novitium Pharma, Epic Pharma Llc, and Hikma. and is included in three NDAs.

The generic ingredient in TAPENTADOL HYDROCHLORIDE is tapentadol hydrochloride. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the tapentadol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tapentadol Hydrochloride

A generic version of TAPENTADOL HYDROCHLORIDE was approved as tapentadol hydrochloride by NOVITIUM PHARMA on January 26^th, 2026.

Summary for TAPENTADOL HYDROCHLORIDE

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	40
Clinical Trials:	69
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TAPENTADOL HYDROCHLORIDE
DailyMed Link:	TAPENTADOL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for TAPENTADOL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Shaukat Khanum Memorial Cancer Hospital & Research Centre	NA
University of Thessaly	PHASE4
Aretaieion University Hospital	N/A

See all TAPENTADOL HYDROCHLORIDE clinical trials

Pharmacology for TAPENTADOL HYDROCHLORIDE

Drug Class	Opioid Agonist
Mechanism of Action	Opioid Agonists

Anatomical Therapeutic Chemical (ATC) Classes for TAPENTADOL HYDROCHLORIDE

N02AX	Other opioids
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

Paragraph IV (Patent) Challenges for TAPENTADOL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUCYNTA	Oral Solution	tapentadol hydrochloride	20 mg/mL	203794	1	2013-12-20
NUCYNTA	Tablets	tapentadol hydrochloride	50 mg, 75 mg, and 100 mg	022304	4	2012-11-20
NUCYNTA ER	Extended-release Tablets	tapentadol hydrochloride	50 mg, 100 mg, 150 mg, 200 mg, and 250 mg	200533	2	2012-11-20

US Patents and Regulatory Information for TAPENTADOL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novitium Pharma	TAPENTADOL HYDROCHLORIDE	tapentadol hydrochloride	SOLUTION;ORAL	219119-001	Jan 26, 2026		RX	No	No
Hikma	TAPENTADOL HYDROCHLORIDE	tapentadol hydrochloride	TABLET;ORAL	205057-003	Feb 10, 2026		DISCN	No	No
Epic Pharma Llc	TAPENTADOL HYDROCHLORIDE	tapentadol hydrochloride	TABLET;ORAL	214378-003	Jan 27, 2026	AB	RX	No	No
Epic Pharma Llc	TAPENTADOL HYDROCHLORIDE	tapentadol hydrochloride	TABLET;ORAL	214378-001	Jan 27, 2026	AB	RX	No	No

Last updated: September 25, 2026

Tapentadol hydrochloride is a differentiated opioid analgesic with dual mu-opioid receptor agonism and norepinephrine reuptake inhibition. Its commercial position is stronger than that of many conventional opioids in selected neuropathic and chronic pain segments, but its growth is constrained by opioid prescribing controls, payer scrutiny, generic competition, and limited use in the United States. The principal branded products are Nucynta and Nucynta ER in the United States and Palexia and Palexia SR in international markets.

Tapentadol Hydrochloride Market Dynamics, Revenue Outlook, Patents, and Generic Entry

What is tapentadol hydrochloride and how does it compete?

Tapentadol hydrochloride is an orally administered centrally acting analgesic. Its pharmacology combines mu-opioid receptor agonism with norepinephrine reuptake inhibition. The mechanism distinguishes it from conventional opioids that rely primarily on mu-opioid activity.

The product is marketed in two principal formats:

Product	Dosage form	Primary positioning	Key commercial issue
Nucynta	Immediate-release tablets	Acute and severe pain	Competition from generic opioid analgesics
Nucynta ER	Extended-release tablets	Severe chronic pain requiring continuous opioid treatment	Formulation patents and opioid prescribing restrictions
Palexia	Immediate-release tablets	Acute and chronic pain	International country-by-country reimbursement
Palexia SR	Extended-release tablets	Chronic severe pain	Generic and tender-price pressure

The U.S. Food and Drug Administration approved Nucynta immediate-release tablets in 2008 and Nucynta ER in 2011. FDA labeling identifies indications including acute pain severe enough to require an opioid analgesic and chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment [1, 2].

Tapentadol has also been used in diabetic peripheral neuropathy markets outside the United States. That positioning is commercially important because neuropathic pain patients may require treatment that addresses both nociceptive and neuropathic symptoms. The label and regulatory status vary by jurisdiction.

How large is the tapentadol hydrochloride market?

Public financial disclosures do not provide a single reliable global market figure for all tapentadol hydrochloride products. The market is fragmented across branded sales, authorized generics, unbranded generics, hospital channels, retail prescriptions, and international distributors.

The commercial market has four structural characteristics:

1. U.S. revenue is concentrated in Nucynta and Nucynta ER.
2. International revenue is distributed across Palexia markets and local generic products.
3. Extended-release products retain greater formulation differentiation than immediate-release tablets.
4. Demand is limited by opioid stewardship programs and payer restrictions.

Tapentadol occupies a premium position relative to many generic opioids because the product has a differentiated mechanism and, in some markets, a lower gastrointestinal adverse-effect burden than conventional opioid comparators. That premium is vulnerable when payers apply step-therapy requirements or require failure on lower-cost generic opioids.

What drives demand for tapentadol?

Demand is supported by:

• Chronic low-back pain and musculoskeletal pain.
• Diabetic peripheral neuropathy in markets where the indication is authorized.
• Patients who do not tolerate conventional opioids.
• Prescribers seeking an opioid with norepinephrine-mediated analgesic activity.
• Hospital and specialist prescribing in selected European and Latin American markets.

Demand is constrained by:

• Controlled-substance prescribing rules.
• Risk-management programs.
• Prior authorization.
• Opioid dose limitations.
• Prescriber preference for lower-cost oxycodone, hydrocodone, tramadol, or morphine.
• The broader shift toward non-opioid analgesics.

Tapentadol is a Schedule II controlled substance in the United States. The scheduling status places it in the same broad regulatory control category as other potent opioids, despite its pharmacologic differences [3].

What is the financial trajectory for Nucynta and Palexia?

The financial trajectory is mature rather than high-growth. Tapentadol is an established product with residual pricing power in branded extended-release formulations, but the market does not have the characteristics of a newly launched specialty medicine.

In the United States, Collegium Pharmaceutical has been the key commercial owner of Nucynta. Collegium acquired the Nucynta franchise from Depomed in 2017. The company’s broader revenue base includes Xtampza ER, Nucynta, and other products, so consolidated company revenue does not equal tapentadol revenue [4].

U.S. commercial trajectory

Nucynta’s U.S. trajectory has followed this pattern:

Period	Commercial condition	Financial implication
2008-2011	Launch of immediate-release and extended-release products	Initial premium pricing and physician adoption
2012-2016	Expansion in chronic and neuropathic pain segments	Brand development before major generic pressure
2017 onward	Ownership transition to Depomed and then Collegium	Portfolio monetization and commercial rationalization
2020-2024	Opioid-market controls and payer pressure	Lower volume growth, reliance on net pricing and retention
Post-exclusivity period	Generic and authorized-generic exposure	Likely price erosion and channel fragmentation

Nucynta is economically more valuable as a portfolio product than as a standalone growth engine. Its contribution can support cash flow, but its long-term trajectory depends on the duration of formulation protection, the timing of generic approvals, and the company’s ability to retain specialists and existing users.

International commercial trajectory

Outside the United States, Grünenthal has been closely associated with Palexia commercialization and licensing. International sales depend on national reimbursement decisions, tender systems, reference pricing, and local generic penetration.

European markets have more centralized price controls than the United States. A successful launch in one jurisdiction does not create equivalent pricing power elsewhere. Palexia’s commercial performance therefore depends on market access execution rather than a single global price strategy.

When does tapentadol lose regulatory exclusivity?

Tapentadol’s principal U.S. regulatory exclusivity periods have expired.

FDA milestone	Date
Nucynta immediate-release approval	2008
Nucynta ER approval	2011
NCE exclusivity for the original product	Expired
Current market status	Patent and approval-specific, with generic-entry analysis required

Regulatory exclusivity and patent protection are separate. The expiration of new chemical entity exclusivity does not automatically permit generic launch if Orange Book-listed patents remain enforceable or if a generic applicant has not obtained FDA approval.

Generic applicants can file an Abbreviated New Drug Application with a Paragraph III certification, which accepts patent expiry, or a Paragraph IV certification, which asserts that listed patents are invalid, unenforceable, or not infringed [5].

What patents protect tapentadol hydrochloride products?

Tapentadol patent protection has historically included composition-of-matter, formulation, and method-of-use claims. The most commercially relevant protection has centered on extended-release dosage forms rather than the basic active ingredient alone.

Composition and active-ingredient patents

The foundational tapentadol patent family covers substituted phenyl compounds with analgesic activity. U.S. Patent No. 6,248,737 is commonly associated with the tapentadol compound family. Its original term was substantially consumed before the current commercial period, limiting its ability to block later generic entry by itself.

Extended-release formulation patents

Nucynta ER and comparable sustained-release products have relied on formulation claims involving:

• Controlled release of tapentadol hydrochloride.
• Tablet composition and release kinetics.
• Dose strengths suitable for twice-daily administration.
• Excipients and matrix technologies.
• Pharmacokinetic profiles designed to maintain exposure over an extended interval.

Formulation patents can delay generic competition when they remain listed in the Orange Book and withstand Paragraph IV litigation. Their practical value depends on claim scope, validity, infringement evidence, and whether a generic applicant can design around the claimed release system.

Method-of-use patents

Method-of-use protection may cover treatment of pain conditions, including chronic pain or neuropathic pain. These patents are generally less effective against generic entry than composition or formulation patents because a generic applicant may use a Section viii statement to carve out a patented indication from its label, where FDA requirements permit the omission.

A method-of-use patent can still create litigation risk if the proposed generic label, promotional activity, or product instructions encourage the patented use.

What is the Orange Book status of Nucynta?

Nucynta and Nucynta ER have been subject to Orange Book patent listings associated with the branded products. The operative analysis requires review of the current FDA Approved Drug Products with Therapeutic Equivalence Evaluations database, including:

• Listed patent numbers.
• Patent expiration dates.
• Drug substance and drug product classifications.
• Reference listed drug status.
• Approved generic applicants.
• Therapeutic-equivalence codes.

The Orange Book is the controlling public source for U.S. listed-patent status, while FDA approval letters and the approved labeling establish the scope of the reference product’s approved uses [5, 6].

Because listed patents may expire, be delisted, or become irrelevant to a specific generic application, a historical patent table should not be treated as a current launch forecast without matching it to the latest Orange Book record.

Which companies are challenging tapentadol patents?

Generic competition can arise from large multinational generic manufacturers, specialty generic companies, and regional suppliers. Publicly reported challenges have involved applicants seeking approval for immediate-release or extended-release tapentadol products, with the competitive set changing as patents expire and ANDAs are approved.

The principal commercial competitors include manufacturers with established opioid and controlled-substance infrastructure, such as:

• Teva Pharmaceutical Industries.
• Hikma Pharmaceuticals.
• Amneal Pharmaceuticals.
• Par Pharmaceutical and other Endo-related entities.
• Viatris and other large generic suppliers, depending on product and jurisdiction.

The identity of an ANDA filer does not establish an imminent launch. A filer may remain subject to a 30-month stay, settlement restrictions, regulatory deficiencies, manufacturing constraints, or a negotiated launch date.

What patent litigation affects tapentadol hydrochloride?

Tapentadol litigation has generally focused on whether generic products infringe extended-release formulation patents and whether those patents are valid and enforceable.

The main litigation questions are:

1. Whether the generic release profile falls within the asserted claims.
2. Whether the formulation claims are obvious in view of earlier controlled-release opioid technologies.
3. Whether the patent specification adequately supports the claimed release characteristics.
4. Whether the generic label induces infringement of a patented method of use.
5. Whether settlement terms establish an authorized-generic or licensed launch pathway.

Patent litigation is commercially meaningful because an early settlement can convert uncertain litigation into a fixed generic-entry date. A later settlement can preserve branded revenue but still create an unavoidable erosion event.

What generic entry risks exist for tapentadol?

Generic entry risk is highest for immediate-release tapentadol and lower, but not eliminated, for extended-release products with enforceable formulation patents.

Product segment	Generic risk	Expected commercial effect
Immediate-release tapentadol	High after core protection expires	Rapid price erosion and pharmacy substitution
Extended-release tapentadol	Moderate to high, depending on formulation patents	Slower erosion if only a few suppliers launch
International Palexia products	Market-specific	Reimbursement and tender-driven price reductions
Authorized generic	High strategic impact	Protects volume but shifts revenue from branded to lower-priced product

A typical generic-launch sequence is:

• First approved generic: limited initial competition and relatively moderate erosion.
• Second through fourth entrants: accelerated price compression.
• Broad generic supply: substantial reduction in branded prescription volume.
• Authorized generic: partial retention of manufacturing and distribution economics.

For a controlled substance, supply-chain qualification and DEA compliance can slow commercial rollout. The delay can benefit the branded product temporarily, but it does not remove the underlying price risk.

How strong is the tapentadol patent estate?

The estate is mixed.

The basic active-ingredient protection is less important than it was during the launch period because the foundational compound patents are old. The residual strength lies in extended-release formulation claims, method-of-use patents, and any continuing pediatric, regulatory, or jurisdiction-specific rights.

Patent category	Relative strength	Commercial relevance
Active ingredient	Low to moderate in the current period	Limited ability to block mature generic products
Extended-release formulation	Moderate	Main source of differentiated protection
Method of use	Low to moderate	Vulnerable to label carve-outs
Manufacturing process	Moderate in narrow cases	Can create technical barriers but rarely blocks all alternatives
International patents	Variable	Depends on national prosecution and expiry

The estate is stronger where claims cover a specific release architecture and weaker where protection depends on broad pain-treatment language.

What manufacturing and intellectual-property barriers affect entry?

Tapentadol generic manufacturers face several operational barriers:

• Controlled-substance registration and quota management.
• Secure handling and recordkeeping.
• Specialized analytical testing for release profiles.
• Bioequivalence requirements for extended-release tablets.
• Scale-up risk involving matrix uniformity and dissolution performance.
• Distribution controls for retail and institutional channels.
• Stability data requirements across dosage strengths.

Extended-release products require more than reproducing the active ingredient. The generic must demonstrate acceptable pharmacokinetic and in vitro performance under FDA standards. These requirements can reduce the number of early entrants, especially where the reference product uses a complex release matrix.

How does tapentadol compare with competing analgesics?

Product	Mechanism	Commercial advantage	Commercial weakness
Tapentadol	Mu-opioid agonism plus norepinephrine reuptake inhibition	Differentiated pharmacology and extended-release positioning	Controlled-substance restrictions and higher cost
Tramadol	Mu-opioid activity plus serotonin and norepinephrine effects	Low-cost, broad generic availability	Variable metabolism and seizure/serotonergic concerns
Oxycodone	Primarily mu-opioid agonism	Familiarity and broad supply	High abuse liability and intense scrutiny
Hydrocodone	Primarily mu-opioid agonism	Strong U.S. prescriber familiarity	Generic competition and regulatory controls
Buprenorphine	Partial mu-opioid agonism	Lower respiratory-depression risk in some contexts	Different dosing, regulatory, and clinical positioning

Tapentadol’s strongest competitive argument is differentiation in patients requiring opioid analgesia with a neuropathic component. Its weakest position is routine acute pain, where inexpensive generic alternatives generally dominate.

What licensing deals and ownership changes matter?

The key U.S. commercial ownership change was Depomed’s acquisition of the Nucynta franchise from Janssen-related entities in 2015, followed by Collegium’s acquisition of Nucynta from Depomed in 2017. These transactions transferred a mature controlled-substance franchise into companies focused on specialty pain portfolios [4, 7].

International commercialization has involved Grünenthal and regional partners. Licensing and distribution arrangements are important because Palexia sales are not governed by a single worldwide commercial structure.

Ownership affects:

• Field-force deployment.
• Payer contracting.
• Authorized-generic strategy.
• Patent litigation funding.
• Manufacturing arrangements.
• Product-line bundling with other pain medicines.

What is the FDA regulatory status of tapentadol?

Tapentadol products are FDA-approved prescription opioid analgesics. The regulatory profile includes:

• Schedule II controlled-substance status in the United States.
• Immediate-release and extended-release formulations.
• Boxed warnings for addiction, abuse, misuse, life-threatening respiratory depression, accidental ingestion, neonatal opioid withdrawal, and risks associated with benzodiazepines or other central nervous system depressants.
• Risk-management requirements reflected in labeling and opioid prescribing controls [1, 2, 3].

There is no biosimilar pathway for tapentadol because it is a chemically synthesized small molecule. Competition proceeds through the ANDA pathway rather than through biologic license applications or biosimilar applications.

What generic launch scenarios should investors expect?

Three scenarios are commercially relevant.

Early limited-entry scenario

One or two generic suppliers enter while extended-release patents or settlements constrain broader competition. Branded volume declines, but net price remains relatively resilient.

Multi-entrant erosion scenario

Several ANDA holders launch after patent expiry or settlement. Pharmacy substitution increases, branded prescriptions fall, and net pricing compresses sharply.

Authorized-generic defense scenario

The brand owner or licensee launches an authorized generic or licenses a third party. This preserves some volume and manufacturing economics but transfers revenue from the branded product to a lower-priced channel.

The highest-risk asset is immediate-release Nucynta. Nucynta ER may retain more value if generic applicants face formulation complexity, but the long-term outcome remains generic erosion rather than durable exclusivity.

What is the revenue exposure for manufacturers?

For Collegium, tapentadol is part of a broader commercial portfolio rather than the sole revenue driver. This reduces company-wide exposure but does not eliminate product-level risk. A decline in Nucynta revenue would affect portfolio mix, gross margin, sales-force efficiency, and cash available for debt repayment or business development.

For Grünenthal and regional partners, Palexia exposure is more geographically dispersed. The impact of generic entry will vary by country because reimbursement and patent expiry dates differ.

Key financial variables are:

• Prescription retention among chronic-pain patients.
• Net price after rebates.
• Number of generic entrants.
• Timing of authorized-generic launch.
• Manufacturing cost per tablet.
• Controlled-substance inventory requirements.
• International tender outcomes.
• Litigation and settlement costs.

Key Takeaways

• Tapentadol hydrochloride is a mature, differentiated opioid analgesic marketed primarily as Nucynta, Nucynta ER, Palexia, and Palexia SR.
• Its commercial value is concentrated in extended-release formulations and selected neuropathic-pain markets.
• U.S. regulatory exclusivity has expired; remaining protection depends mainly on formulation, method-of-use, and jurisdiction-specific patents.
• Immediate-release generic risk is high. Extended-release risk is more dependent on formulation patents, ANDA timing, and litigation settlements.
• Collegium is the key U.S. commercial owner of Nucynta, while Grünenthal has been central to international Palexia commercialization.
• Tapentadol has no biosimilar risk because it is a small-molecule drug.
• Revenue is likely to follow a mature-product trajectory: stable or declining volume, payer pressure, and significant downside when multiple generics enter.
• Controlled-substance manufacturing and extended-release bioequivalence requirements can delay entry but are unlikely to prevent eventual price erosion.

FAQs

Is tapentadol hydrochloride still patent protected?

Some product and formulation rights may remain relevant by jurisdiction and dosage form, but foundational active-ingredient protection is old. Current U.S. status must be determined from the latest Orange Book listings and individual patent records.

Is Nucynta ER stronger than Nucynta for protecting revenue?

Yes. Nucynta ER has greater formulation complexity and historically greater reliance on release-profile patents. Immediate-release tapentadol is more exposed to conventional generic substitution.

Can generic tapentadol be launched before all Nucynta patents expire?

A generic applicant may launch after a successful Paragraph IV challenge, a settlement date, patent invalidation, non-infringement finding, or an authorized-generic arrangement. A Paragraph III certification generally delays launch until the relevant patent expiry date.

Is tapentadol safer than oxycodone?

Tapentadol has different pharmacology and may have a different adverse-effect profile in some patients, but it remains a potent Schedule II opioid with risks of addiction, misuse, respiratory depression, and overdose. It should not be treated as a low-risk substitute.

Does tapentadol have a biosimilar competitor?

No. Tapentadol is a chemically synthesized small molecule. Potential competitors are generic drugs approved through the ANDA pathway, not biosimilars.

References

1. U.S. Food and Drug Administration. (2023). Nucynta: Tapentadol hydrochloride prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Nucynta ER: Tapentadol hydrochloride extended-release prescribing information. FDA.

3. U.S. Drug Enforcement Administration. (2024). Controlled substance schedules. U.S. Department of Justice.

4. Collegium Pharmaceutical, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

6. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

7. Depomed, Inc. (2017). Current report on Form 8-K: Sale of Nucynta franchise to Collegium Pharmaceutical. U.S. Securities and Exchange Commission.